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Sickle cell disease (SCD) is a genetic disorder in which
emoglobin S (Hb S) predominates in red blood cells. It is
onsidered a signiﬁcant public health issue in Brazil.1–3
Sickle cell anemia (SCA, Hb SS) is the most common sub-
ype of SCD in the world. Although its clinical course is
ariable, patients with SCA generally have the most severe
henotype. SCD also includes the heterozygous combination
f Hb S with other hemoglobin variants (Hb SC, Hb SD-Punjab,
nd others). The combination of Hb S with  thalassemia (Hb
/0 and Hb S/+ thalassemia) leads to other subtypes of SCD
ith a variable relative incidence depending on the ethnic
omposition of the population.4,5
The relative death rate due to hemoglobin disorders in
nder ﬁve-year-old children all over the world is reported to be
.4% of all deaths.6 Morbidity and mortality are especially high
n developing countries.7 Even in developed countries, SCD is
till a signiﬁcant cause of mortality, particularly in adolescents
nd adults.8–10
There are only two newborn-screening cohort studies in
razil, which have reported the death rate for children with
CD. In both studies, it was very high compared to ﬁgures
3eported in developed countries. In Minas Gerais, the crude
eath rate for 1396 children (all subtypes) diagnosed in a
even-year period was 5.6%. The Kaplan–Meier estimated
robability of death at ﬁve years of age for children with Hb SS
r Hb S/0 thalassemia was 10.6% (standard error: 1.4). In Rio
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eserved.de Janeiro,1 the crude death rate for 912 children (all subtypes)
in a ten-year period of newborn screening was 4.2%. The main
causes of death in both cohorts were infection (including acute
chest syndrome which in children is indistinguishable from
pneumonia) and acute splenic sequestration.
Unfortunately, the crude death rate for the newborn cohort
in Minas Gerais has not signiﬁcantly decreased over the years.
In a recent report that will be published in the Jornal de Pedi-
atria (RJ),11 the death rate in the last seven-year period of
observation was 5.12% compared to 5.43% (p-value = 0.72) in
the ﬁrst seven years of the study.
In this issue of the Revista Brasileira de Hematologia e
Hemoterapia (RBHH), Lima et al.12 analyze trends in mortality
and hospital admission rates for patients (not only children)
with SCD in a 14-year period, comparing the data before and
after the introduction of a newborn screening program in
Maranhão, a northeastern state in Brazil. The total number
of recorded hospital admissions increased from 128 in the
ﬁrst seven-year period (‘pre-newborn screening’ – 1999–2005)
to 840 in the ‘post-newborn screening’ period (2006–2012).
The rate of hospitalization relative to the total population in
Maranhão increased from 0.315 (pre) to 1.832 (post) per 100,000
persons, indicating a ratio 5.82 times higher and showing ae Minas Gerais (UFMG), Av. Alfredo Balena, 190, sala 267, 30130-100
growth in trend (p-value = 0.04). The median age at admis-
sion dropped from 11.4 years to 8.7 years (p-value = 0.0002).
The mortality rate increased from 0.115 to 0.216, 1.88 times
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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Figure 1 – Hospital admissions for children and adults with r
1
1
1
1
1the main diagnosis of sickle cell diease (CID D57) in Minas
Gerais, Brazil, from 1999 to 2012 (n = 8028).
higher (p-value = 0.59 – non-signiﬁcant). The median age at
death increased from ten years to 14 years (p-value = 0.67 –
non-signiﬁcant). In conclusion, the authors state that “the key
reason for the apparent paradox of increased mortality and
hospitalization rates after the implementation of neonatal
screening is the increased ‘visibility’ of sickle cell disease”.
The invisibility of SCD is also evident when the authors
compare the hospitalization rate for SCD in Maranhão (1.832)
with those in Bahia (1.8), São Paulo (6.0), and Rio de Janeiro
(7.0).13 Considering the relative proportion of Black people
in the total population, Lima et al. have estimated that the
expected number of patients should be very similar in these
states (9–11 thousand) and so the hospitalization rate should
be about the same, which is empirically not true. In this com-
parison, the lower hospitalization rate for Maranhão and Bahia
relative to Rio de Janeiro and São Paulo is due not only to
under-reporting of patients (the ‘invisible’ disease), but also,
probably, to lower level of health care for patients with SCD in
these poorer states demonstrating “the social differences that
exist between regions in Brazil”.12
In Minas Gerais, we  have observed two other pieces of
evidence of the invisibility of SCD. In the aforementioned
study,11 the inclusion of the word sickle (“falciforme”) on the
death certiﬁcates of children who  were known to be patients
with SCD since birth (they tested positive in the newborn
screening and had been followed up in the Fundac¸ão Centro
de Hematologia e Hemoterapia de Minas Gerais – HEMOM-
INAS) increased from the incredible ﬁgure of 42.1% in the
ﬁrst seven-year period to a still low ﬁgure of 60.5% in the last
period. Similar to the data of Maranhão, we  have observed a
steep increase in hospital admissions (n = 8028) for children
and adults registered in the Hospital Information System
(SIH) of the Brazilian National Health Service (SUS) from 1999
to 2012 (data not published yet – Figure 1).14
In conclusion, continuous educational programs directed
to health professionals and to families and patients with SCD
should be boosted in order to increase the ‘visibility’ of the dis-
ease and to decrease the mortality and morbidity caused by it.
Also, as we  have previously stated,3 “the [Brazilian] Ministry
of Health’s program to provide integrated healthcare for peo-
ple with SCD is an ideal toward which patients, their families
and the professionals involved in treating them must work in
order to achieve the objective of improving the current living
conditions and health status of these people”.er. 2 0 1 5;3 7(1):5–6
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